Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Update on treatments for high- and low-risk MDS

Nicolas Bonadies • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Azacitidine Luspatercept Venetoclax

Nicolas Bonadies, MD, Bern University Hospital, Bern, Switzerland, discusses the latest advancements in treatments for both low-risk and high-risk myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Nicolas Bonadies

1:32
Next-generation sequencing for low-risk MDS
Nicolas Bonadies • 5 Mar 2020
1:59
EPO plus G-CSF treatment for MDS
Nicolas Bonadies • 5 Mar 2020

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals